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use and unit prices estimated from other sources. The
level of detail collected in clinical trials varies and deter-
mines which resource costing methods can be used. Using
hospital inpatient data, this study compares three re-
source costing methodologies that utilize varying levels of
information about hospitalizations. METHODS: As part
of project TrEAT, an alcohol-related intervention study,
hospital primary discharge data were collected for HMO
patients. Data from HCUP National Inpatient Sample
(NIS) 2000 are used for estimating unit prices. Three
resource costing methods are applied: 1) a per day unit
price over all hospitalizations; 2) a unit price per day for
each DRG; and 3) a unit price per day for each primary
ICD-9-CM discharge diagnosis. Inpatient costs are calcu-
lated as the product of these unit prices and the observed
inpatient days. Inpatient costs for the intervention and
control groups are compared. RESULTS: For the 1-year
period following study enrollment, method 1 yields
control and intervention group averages of $485($2736)
and $246($1458), respectively. Method 2 produced mean
and standard deviations of costs that were approximately
twice as large, $956($5695) and $543($3755) for the
control and intervention group, respectively. Method 3
produced mean and standard deviations larger than
Method 1 but smaller than Method 2: $691($3740) and
$445($2982) for the control and intervention group,
respectively. Differences between the intervention arms
are greater using Method 2, ($412 versus $238 and
$245). CONCLUSIONS: The level of resource use detail
can affect the results of economic evaluation of clinical
trials. Costing hospitalizations using DRG level data
resulted in larger differences between intervention arms
than methods using ICD-9-CM level data or a ﬁxed per
diem amount.
PMD19
COMMUNITY OR PATIENT PREFERENCES 
FOR COST-UTILITY ANALYSES: DOES IT
MATTER?
Furlong W1, Oldridge N2, Perkins A3, Feeny DH4,
Torrance GW1
1McMaster University, Hamilton, ON, Canada; 2Indiana
University, Indianapolis, IN, USA; 3Regenstrief Institute for
Health Care, Indianapolis, IN, USA; 4University of Alberta,
Edmonton, AB, Canada
OBJECTIVE: To determine if it matters whether we use
community or patient preferences in cost-utility analysis.
METHODS: Patients were randomized within 6 weeks of
acute myocardial infarction to a 2-month cardiac reha-
bilitation intervention (n = 99) or to usual care (n = 102).
Data were collected at baseline and at 2, 4, 8, and 12
months. Community-based preferences for patients’
health states were measured using the Quality of Well-
Being (QWB). Patients’ preferences for their subjectively-
deﬁned health states were measured using the Time
Trade-off (TTO) technique. Agreement between QWB
and TTO measures was assessed using intra-class corre-
lation coefﬁcient (ICC). Responsiveness of each measure
was calculated as the standardized response mean (SRM).
Quality-adjusted life years (QALYs) experienced by each
patient were estimated separately using both QWB and
TTO measurements. Costs, measured from the societal
perspective for each individual patient, included those
borne by the health-care system and the rehabilitation
program and the patients. Incremental cost-utility ratios
were estimated using mean costs and QALYs for the study
groups. QWB-based and TTO-based cost-utility results
were compared. RESULTS: Agreement between QWB
and TTO scores varies from negligible (ICC = 0.069) at
baseline to strong (ICC = 0.607) at 12-month assessment.
TTO scores are higher than QWB scores (p < 0.01). QWB
and TTO scores for both groups of patients improved (p
< 0.05) between baseline and 12 months. SRMs are 0.64
for QWB and 0.34 for TTO. QALYs gained by rehabili-
tation are 0.011 using QWB and 0.040 using TTO, at a
cost (US $ 2001) of $702 per patient. The cost-utility of
rehabilitation is $62,000 per QWB-based QALY gained
and $17,500 per TTO-based QALY gained. CONCLU-
SIONS: The QWB and TTO results are different. This
may not be generalizable but is cause for concern because
it suggests that the cost-effectiveness of an intervention
may differ depending upon whether community or
patient preferences are used.
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OBJECTIVES: In Thailand, economic evaluation of
medical technology has been increasingly used as a tool
to aid decision making particularly since the economic
crisis in 1997. Despite the increased number of economic
evaluation studies, there has been no study evaluating
their quality. The purpose of this study is to systemati-
cally identify all economic evaluation studies in Thailand
and to assess their quality. METHODS: We performed a
systematic search for economic evaluation studies
through MEDLINE (1966–2002), Thai index Medicus
(1918–2002), and Thai Thesis Online (1966–2002). In
addition, we electronically searched for “research
reports” or “theses” through 8 major university libraries
to identify potential studies. Only Thai studies evaluating
both cost and outcomes were included. All studies were
evaluated using a standardized abstraction form, which
was developed based on Drummond’s 10-item checklist.
RESULTS: A total of 6488 studies was identiﬁed from the
search but only 49 published and 57 unpublished studies
met inclusion criteria. After complete assessments of pub-
